WillItSurvive
Pharma and healthcare groups · subsidiary of SK Inc. · South Korea

SK Biopharmaceuticals

skbp.com ↗

Korean biopharma selling Xcopri, an FDA-approved epilepsy drug, mostly in the US market.

Defensible for now
Assessed 26 July 2026 · Evidence as of 26 July 2026
Real protection, with named pressure against it.
On the recordSince 26 July 2026 · Checkable from Jan 31, 2027 · Every call on the record Checkpoint: FDA PDUFA decision on cenobamate oral-suspension NDA
The call

One drug drives nearly all revenue, growing fast in the US while patents hold, with tariffs and a rival epilepsy candidate as the main watch points.

SK Biopharmaceuticals sells Xcopri, an FDA-approved epilepsy medicine that is growing fast in the U.S. and protected by patent until around 2027-2028, which makes it hard for competitors like Pfizer or Jazz Pharmaceuticals to copy. Big companies like Xenon Pharmaceuticals are testing new epilepsy drugs, but none are approved yet, so Xcopri has breathing room for now. The real threat is a 15 percent tariff on Korean drugs starting in 2026 that could squeeze profits unless the company moves manufacturing or cuts a pricing deal with the U.S. government by early 2029.

Why
01
AI pressure: None apparent. Xcopri is a patented small-molecule already on the market; AI drug-discovery labs target future pipelines, not this approved asset. Could AI do the core job? Unlikely.
02
Bigger players: Xenon Pharmaceuticals (XEN1101). Xenon's Kv7 modulator XEN1101 is in Phase 3 for focal epilepsy, a potential rival mechanism, but not yet approved or selling. Could a giant copy it? No, they are blocked.
03
What protects it. Cenobamate's US patents plus FDA market exclusivity and an established base of prescribing neurologists.
What would change this call
FDA decision on cenobamate oral-suspension NDA by Jan 31, 2027. Shows whether SK Biopharmaceuticals can widen Xcopri's dosing options and extend exclusivity.
Xenon Pharmaceuticals XEN1101 Phase 3 readout and any FDA approval by 2027-2028. Would show a real epilepsy-drug competitor entering the market Xcopri now leads.
Whether SK Life Science signs a U.S. onshoring/MFN-pricing deal before the Jan 2029 tariff deadline. Determines if the 15% U.S. tariff on Korean patented drugs cuts Xcopri's margins.
Key numbers
  • FY2025 revenue 706.7 billion won, up 29.1% YoY (2025-12-31)
  • Q3 2025 US Xcopri sales $117M, up 51.9% YoY (2025-09-30)
  • FDA untitled letter over Xcopri TV ad claims (2025-09-30)
Named risks
  • Over 90% of revenue concentrated in a single drug, Xcopri (cenobamate). Severity: high
  • New 15% US tariff on Korean patented drugs from April 2026 pressures margins. Severity: high
  • FDA untitled letter (Sept 2025) signals marketing compliance risk, possible further escalation. Severity: medium
  • Unproven pipeline: carisbamate still in Phase 3 as of Jan 2026, radiopharma assets early-stage. Severity: medium
  • Emerging Kv7 modulator rivals (Xenon XEN1101) could erode epilepsy market share if approved. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
UCBcontestingLong-time epilepsy leader but cannot clone patent-protected Xcopri, approved 2019
PfizercontestingLegacy anti-seizure drug Lyrica competes in broader ASM market as of 2026
GSKcontestingIncumbent CNS player in overall epilepsy drug market, no direct cenobamate rival
Jazz PharmaceuticalscontestingBoth a licensing partner (Sunosi) and competitor via new Saniona-licensed SAN2355
Xenon PharmaceuticalscontestingXEN1101 in Phase 3 focal epilepsy as of mid-2026, not yet FDA-approved
Questions people ask
Is SK Biopharmaceuticals profitable in 2026?
Yes. For FY2025 (ended Dec 31, 2025) SK Biopharmaceuticals reported net profit of 253.3 billion won (+11.6% YoY) and operating profit of 203.9 billion won (+111.7% YoY), driven largely by US Xcopri sales, per its Feb 6, 2026 earnings report.
What is SK Biopharmaceuticals' biggest competitor?
In US focal epilepsy, incumbents UCB, Pfizer, GSK, Novartis and Jazz Pharmaceuticals dominate the anti-seizure market, though none can legally clone SK's patent-protected Xcopri (cenobamate), which the FDA approved in 2019.
Could AI replace SK Biopharmaceuticals?
No, AI can't replicate an FDA-approved, patent-protected drug or physician trust. SK uses generative AI internally; CEO Lee Dong-hoon said in June 2025 'AI is no longer optional but a core component in drug development,' via tools like Cheiron for literature review, not commercialization.
Who owns SK Biopharmaceuticals?
SK Biopharmaceuticals is majority owned by parent SK Inc. (formerly SK Holdings), which retained roughly 75% ownership after the company's July 2020 KOSPI IPO, per Korea Herald reporting from June 24, 2020.
Why did SK Biopharmaceuticals pull its Xcopri TV ad?
The FDA issued an untitled letter on Sept 30, 2025 citing misleading safety claims in Xcopri's first-ever TV ad campaign; SK Life Science pulled the ad and planned a reworked relaunch for H1 2026, per Korea Biomed reporting Nov 26, 2025.
What's the tariff risk for SK Biopharmaceuticals?
A US Section 232 proclamation effective April 3, 2026 imposed a 15% tariff on Korean patented drugs, previously zero; SK Life Science can only reach 0% through Jan 2029 by signing an onshoring plus MFN-pricing deal, a major swing factor for Xcopri margins.
Timeline
  • 2026-06-15FDA accepts NDA for cenobamate oral suspension, PDUFA date set Jan 31, 2027
  • 2026-05-20South Korea cuts generic drug price calculation rate from 53.55% to 45%
  • 2026-04-03US Section 232 tariff imposes 15% duty on Korean patented drugs, previously zero
  • 2026-02-06FY2025 results: revenue 706.7bn won (+29.1%), net profit 253.3bn won (+11.6%)
  • 2025-11-26SK Life Science pulls Xcopri TV ad after FDA letter, plans H1 2026 relaunch
  • 2025-09-30FDA issues untitled letter over misleading Xcopri ad safety claims
  • 2025-08-05Q2 2025 US Xcopri sales surpass $111M, first quarter over $100M
  • 2025-06-18SK Biopharmaceuticals signs MOU with PhnyX Lab for AI drug-development tooling
  • 2020-07-02SK Biopharmaceuticals IPOs on KOSPI, shares double on debut
  • 2019-11-21FDA approves cenobamate (Xcopri) for focal epilepsy
Revision history
26 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources